SCHEMBL1776646

SCHEMBL1776646

CC(C)CC(=O)N[C@@H]1CCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
KDM1A O60341 1/20 0.43
EPHX1 P07099 3/20 0.41
KDM5A P29375 1/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 4/20 0.37
SLC6A3 Q01959 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
SLC6A1 P30531 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12413711 1.00 KCNH2 (0.43) KCNH2GNAI3GNAO1GNAI1KDM1A
SCHEMBL12413713 0.90 MAPK1 (0.44) KCNH2EPHX1KDM5ARAB9ACYP3A4
SCHEMBL11890392 0.89 EPHX1 (0.53) GNAI3GNAO1GNAI1EPHX1KDM5A
Hydrochloric Acid SCHEMBL11625982 0.88 GNAI3 (0.55) GNAI3GNAO1GNAI1EPHX1KDM5A
SCHEMBL17066213 0.85 SMN1; SMN2 (0.40) EPHX1KDM5ARAB9ACYP3A4HPGD
SCHEMBL13188228 0.83 GNAI3 (0.48) KCNH2GNAI3GNAO1GNAI1KDM1A
SCHEMBL12403611 0.80 KCNH2 (0.52) KCNH2GNAI3GNAO1GNAI1KDM1A
SCHEMBL4782330 0.80 KCNH2 (0.52) KCNH2GNAI3GNAO1GNAI1KDM1A
SCHEMBL10444151 0.80 KCNH2 (0.52) KCNH2GNAI3GNAO1GNAI1KDM1A
SCHEMBL18199497 0.79 RAB9A (0.49) EPHX1KDM5ARAB9ACYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943659-B2 cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-17 US disclosed
EP-2113500-A1 MAPK/ERK kinase inhibitors Takeda Pharmaceutical Company Limited (JP) 2009-11-04 EP disclosed
EP-2089359-A2 MAPK/ERK KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2009-08-19 EP disclosed
US-20080188453-A1 MAPK/ERK KINASE INHIBITORS TAKEDA CALIFORNIA, INC. 2008-08-07 US disclosed
WO-2008055236-A2 MAPK/ERK KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188453-A1 MAPK/ERK KINASE INHIBITORS MAPK1, MAP3K1, MAP3K7 KCNH2 4293/4885GNAI3 973/4885GNAO1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.